AU2022238886A1 - Purine derivatives as anticancer agents - Google Patents
Purine derivatives as anticancer agents Download PDFInfo
- Publication number
- AU2022238886A1 AU2022238886A1 AU2022238886A AU2022238886A AU2022238886A1 AU 2022238886 A1 AU2022238886 A1 AU 2022238886A1 AU 2022238886 A AU2022238886 A AU 2022238886A AU 2022238886 A AU2022238886 A AU 2022238886A AU 2022238886 A1 AU2022238886 A1 AU 2022238886A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- cancer
- compound
- cycloalkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162460P | 2021-03-17 | 2021-03-17 | |
| US63/162,460 | 2021-03-17 | ||
| PCT/US2022/020700 WO2022197892A1 (en) | 2021-03-17 | 2022-03-17 | Purine derivatives as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022238886A1 true AU2022238886A1 (en) | 2023-09-14 |
Family
ID=81327909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022238886A Abandoned AU2022238886A1 (en) | 2021-03-17 | 2022-03-17 | Purine derivatives as anticancer agents |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240059689A1 (https=) |
| EP (1) | EP4308566A1 (https=) |
| JP (1) | JP2024511996A (https=) |
| KR (1) | KR20240006509A (https=) |
| CN (1) | CN117425656A (https=) |
| AU (1) | AU2022238886A1 (https=) |
| BR (1) | BR112023018799A2 (https=) |
| CA (1) | CA3212292A1 (https=) |
| IL (1) | IL305991A (https=) |
| MX (1) | MX2023010909A (https=) |
| WO (1) | WO2022197892A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312642A (en) | 2021-11-12 | 2024-07-01 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| EP4430049A4 (en) * | 2021-11-12 | 2025-12-17 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof |
| TW202509030A (zh) | 2023-05-08 | 2025-03-01 | 美商譚格醫療公司 | 化合物及使用方法 |
| WO2024233665A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| CN117024253A (zh) * | 2023-08-14 | 2023-11-10 | 江西阿尔法高科药业有限公司 | 一种药用级麝香草酚特定杂质的制备方法 |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| TW202539659A (zh) | 2024-01-10 | 2025-10-16 | 美商維瑞斯治療股份有限公司 | Ｄｎａ損傷修復途徑的新穎抑制劑 |
| WO2025256544A1 (zh) * | 2024-06-11 | 2025-12-18 | 福建盛迪医药有限公司 | 一种1-氨烷基修饰的呋喃核糖衍生物的制备方法 |
| CN119751316A (zh) * | 2024-12-20 | 2025-04-04 | 江南大学 | 一种1-苯基三氟甲基n-（氟磺酰基）氨基甲酸酯化合物的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI378933B (en) * | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| CN102127070A (zh) * | 2010-01-15 | 2011-07-20 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
| JP2011236198A (ja) * | 2010-04-13 | 2011-11-24 | Daiichi Sankyo Co Ltd | モルホリノプリン誘導体 |
| CN108473495B (zh) * | 2015-11-20 | 2022-04-12 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| US11485736B2 (en) * | 2018-12-20 | 2022-11-01 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
-
2022
- 2022-03-17 WO PCT/US2022/020700 patent/WO2022197892A1/en not_active Ceased
- 2022-03-17 IL IL305991A patent/IL305991A/en unknown
- 2022-03-17 JP JP2023557285A patent/JP2024511996A/ja active Pending
- 2022-03-17 CN CN202280035481.2A patent/CN117425656A/zh active Pending
- 2022-03-17 BR BR112023018799A patent/BR112023018799A2/pt unknown
- 2022-03-17 AU AU2022238886A patent/AU2022238886A1/en not_active Abandoned
- 2022-03-17 CA CA3212292A patent/CA3212292A1/en active Pending
- 2022-03-17 MX MX2023010909A patent/MX2023010909A/es unknown
- 2022-03-17 EP EP22717473.7A patent/EP4308566A1/en active Pending
- 2022-03-17 KR KR1020237035424A patent/KR20240006509A/ko active Pending
-
2023
- 2023-09-15 US US18/468,385 patent/US20240059689A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240006509A (ko) | 2024-01-15 |
| IL305991A (en) | 2023-11-01 |
| CN117425656A (zh) | 2024-01-19 |
| MX2023010909A (es) | 2024-02-13 |
| JP2024511996A (ja) | 2024-03-18 |
| WO2022197892A1 (en) | 2022-09-22 |
| EP4308566A1 (en) | 2024-01-24 |
| BR112023018799A2 (pt) | 2023-12-12 |
| CA3212292A1 (en) | 2022-09-22 |
| US20240059689A1 (en) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022197892A1 (en) | Purine derivatives as anticancer agents | |
| US20240182481A1 (en) | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer | |
| US11999727B2 (en) | Compounds and methods of use | |
| US12403137B2 (en) | Compounds and methods of use | |
| US11986471B2 (en) | Compounds and methods of use | |
| WO2024233605A1 (en) | Compounds and their use against cancer | |
| WO2023146991A1 (en) | Compounds and methods of use | |
| AU2023213736A1 (en) | Compounds and methods of use | |
| US20250171432A1 (en) | Compounds and methods of use | |
| WO2023146990A1 (en) | Compounds and methods of use | |
| WO2024233665A1 (en) | Compounds and their use against cancer | |
| US20260062426A1 (en) | Cyclin dependent kinase degraders and methods of use thereof | |
| WO2026090589A1 (en) | Heterocyclic hbs1l degraders | |
| WO2026073277A1 (en) | Substituted piperidine-diones inactivating hbs1l | |
| WO2017151625A1 (en) | 4,9-dioxo-4,9-dihydronaphtho(2,3-b)furan-3-carboxmide derivatives and uses thereof for treating proliferative diseases and infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO TANGO THERAPEUTICS, INC. AND MEDIVIR AB |
|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |